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ABSTRACT
Hereditary nephrogenic diabetes insipidus (NDI) is 
caused by mutations in either the X-chromosomal 
gene encoding the vasopressin V2-receptor or in the 
autosomal gene encoding aquaporin-2. Expressed in 
Xenopus oocytes, the AQP2 gene mutations found in 
NDI have been shown to reduce the stability of the 
encoded protein. This study investigated the in vivo 
stability of mutant and wild-type aquaporin-2 proteins 
by measuring their excretion in urine of NDI patients 
and healthy individuals. On immunoblots, the urine 
samples from healthy volunteers revealed clear 
aquaporin-1 and aquaporin-2 signals in antidiuretic 
but not diuretic states. In the urine of a female patient, 
whose NDI is explained by low expression of the 
wild-type V2-receptor gene, aquaporin-2 excretion 
was high and comparable with that in a healthy 
individual during antidiuresis. In the urine of a male 
patient with a non-sense mutation in the V2-receptor 
gene, a weak aquaporin-2 signal was detected, in 
NDI patients with mutations in the aquaporin-2 gene, 
aquaporin-2 could not be detected in urine, suggest­
ing a low stability of mutant aquaporin-2 proteins. In 
four out of seven NDI patients, aquaporin-1 excretion 
was relatively high, which suggests a compensatory 
increase in proximal reabsorption in NDI.
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In humans, the kidney produces 180 L of glomeru­lar filtrate daily, of which normally more than 99% 
is reabsorbed. In this process, molecular water chan­
nels, aquaporins, have been shown to play an impor-
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tant role (1). In the proximal tubules and descending 
limbs of Henle, the constitutive reabsorption of 165 L 
is presumably mediated by aquaporin-1 (AQP1) (1). 
Depending on the need of the body, the remaining 15 
L can either be reabsorbed in the collecting duct in 
response to the antidiuretic hormone, arginine vaso­
pressin (AVP), or be expelled. Upon the binding of AVP 
to its V2-receptor (V2R) in the basolateral membrane of 
collecting duct cells, a chain of signaling events is 
initiated, resulting in the insertion of vesicles contain­
ing aquaporin-2 (AQP2) into the apical membrane and 
increased reabsorption of water (2).
In patients suffering from nephrogenic diabetes in­
sipidus (NDI), the kidney fails to concentrate urine in 
response to AVP, In the majority of these patients, the 
disease is caused by a mutation in the X-chromo­
somal V2R gene (3-5). Mutations in the autosomal 
AQP2 gene, which has been assigned to chromosome 
12(6,7), have been shown to be responsible for NDI in 
families that show an autosomal mode of inheritance, 
Until now, a one-nucleotide deletion and three mis- 
sense mutations in the AQP2 gene of NDI patients 
have been described (8,9). From expression studies in 
oocytes, it appeared that these missense AQP2 pro­
teins were nonfunctional and were equally or less 
stable than wild-type AQP2 (10). On immunoblots, 
both AQP1 and AQP2 have been detected in urine 
{7,11), thereby enabling the assessment of the in vtoo 
stability of mutant AQP2 proteins. Because the urine 
osmolality of NDI patients is usually below 200 
mosmol/kg, we first tested whether AQP1 and AQP2 
can be detected in diuretic states in healthy individu­
als. We subsequently analyzed the urine from seven 
NDI patients, four of whom have a mutation in the 
AQP2 gene and three who have a mutation in the V2R 
gene, to address the stability of mutant AQP2 proteins 
in uiuo and the presence of wild-type AQP2 in NDI 
patients with mutations in the V2R- In addition, we 
assessed whether urinary AQP1 expression levels are 
different in NDI patients.
METHODS 
Urine Samples
Healthy Persons. Urine samples from four healthy volun­
teers (aged 24, 25, 33, and 51 yr; 1 woman, 3 men) were 
collected according to the following protocol. After 3 h of 
drinking at least 0.75 L water per h, a diuretic (D) urine 
sample was collected. The next morning, after emptying the 
bladder before going to sleep and fluid restriction from 8 p.m. 
to 7 a.m., an antidiuretic (AD) urine sample was obtained. 
The osmolality of the urine samples was determined by 
standard procedures. To determine the (sub)cellular frac-
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tions containing AQP1, AQP2, and Tamm-Horsfall proteins 
(THP), a fractionation protocol was adopted that efficiently 
separates intracellular vesicles from plasma membranes as 
tested for AQP1 and AQP2 on rat kidney tissue (12). In brief, 
an antidiuretic urine sample was divided into two portions 
and subsequently concentrated or consecutively centrifuged 
for 15 mill at 4000 g, 30 min at 17,000 g, and 1 h at 200,000 
g. The supernatant of the 200,000-g fraction was concen­
trated. Cells, nuclei, and large fragments are se dimen ted at 
4000 g, plasma membranes are enriched in the 17,000-g 
pellet, and intracellular vesicles are found in the 200,000-g 
pellet (12). The pellets of the different fractions were resus­
pended in homogenization buffer A (20 mM Tris [pH = 7.41, 5 
mM MgCl2, 5 mM NaHP04, 1 mM EDTA, I mM dithiothreitol, 
100 ¡jlM ouabain, 1 mM phenylmethylsulphonyl fluoride, 5 
¿xg/mL leupeptin and pepstatin, and 80 mM sucrose). For 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), relative volume-equivalents were loaded (i.e., 
the amount of AQP1, AQP2, or THP in the concentrated urine 
is identical to the total amount contained in the fractions).
NDI Patients. Urine samples were collected from four NDI 
patients with mutations in the AQP2 gene and from three 
patients with mutations in the V2R gene (Table 1). The 
patients carrying AQP2 gene mutations are homozygous for a 
deleted nucleotide at Position 463 (originally annotated as 
Position 369) or homozygous for Gly64Arg, Argl87Cvs (9), or 
Alal47Thr (not published) substitutions. The V2R mutations 
found in the male patients consist of a small deletion 
(528del7; originally annotated as 457del7) and a T204N 
substitution (13), respectively, whereas the female patient is 
heterozygous for a two-nucleotide deletion in the Region 
337-340 (14). All nucleotide deletions result in frameshifts,
Urine samples were concentrated by ultrafiltration using 
Amicon stirred cells with YM10 ultrafiltration membranes 
(Amicon Inc., Beverly, MA) according to a protocol provided 
by the manufacturer. Protein concentrations of urine sam­
ples were determined using the BioRad protein assay (Bio- 
Rad, München, Germany).
Immunoblotting
From erythrocyte ghost membranes, prepared according to 
Benneth (15), and urine samples of healthy persons and NDI 
patients, protein equivalents of 18 /u,g were denatured and 
separated by SDS-PAGE as described (10). From the patient 
with the T204N mutation in the V2R, only 10 /xg was avail- 
able. After electrophoresis, the gel was stained with Coomas- 
sie brilliant blue or used for immunoblotting essentially as 
described (16). In brief, proteins were transferred at 4°C for 
105 min at 100 V to 0.45-jum nitrocellulose membranes 
(Schleicher and Schuell, Dassel, Germany) using Towbin 
buffer (17). The efficiency of protein transfer was checked by 
staining membranes with ponceau red. The Western blot was
subsequently analyzed with enhanced chemiluminescence 
(ECL, Amersham, England), to visualize sites of antigen- 
antibody reactions, according to the manufacturer and as 
modified by Sheng and Schuster (18). As primary antibodies 
we used: a 1:50 dilution of a mouse monoclonal antibody 
raised against dog AQP1 (19) (gift from M.L. Jennings, 
Galveston, TX); a 1:3000 dilution of affinity-purified rabbit 
anti-AQP2 immunoglobulins (10); a 1:10000 dilution of goat 
antiserum directed against human THP (Organon Teknika 
Co., West Chester, PA); or a 1:1000 dilution of affinity- 
purified rabbit anti-spectrin antibodies (20) (gift from P. Agre, 
Baltimore, MD). When indicated, a 1;300 dilution of affinity- 
purified rabbit antibodies directed against the N-terminus of 
human AQP1 was used (20) (gift from P. Agre, Baltimore, 
MD). As secondary antibodies, we used a 1:2000 dilution of 
affinity-purified sheep anti-mouse IgG antiserum (whole 
molecule; Sigma Chemical Co., St, Louis, MO), a 1:5000 
diluted affinity-purified goat anti-rabbit IgG antiserum 
(whole molecule; Sigma), or a 1:2000 diluted affinity-purified 
rabbit anti-goat IgG antiserum (whole molecule; Dakopatts 
Corp., Glostrup, Denmark). All three secondary antibodies 
were coupled to horseradish peroxidase. When indicated, 
luminographic signals were scanned with an LKB Uitrascan 
XL laser densitometer (Pharmacia LKB, Sweden).
RESULTS 
Healthy Individuals
To investigate AQP2 excretion in urine, D and AD 
urine samples from four healthy volunteers were col­
lected and concentrated. The osmolality of D urine 
samples were 100 mosmol/kg or less, whereas the 
osmolality of AD tirine samples were > 700 mosmol/ 
kg. Coomassie staining of a gel loaded with 18-/jg 
protein equivalents of the urine samples revealed a 
striking difference in protein pattern between D and 
AD urine samples, including considerably more low- 
molecular-mass proteins (LMMP) (i.e., < 66 kd) in D 
urine samples (Figure 1). These differences were also 
apparent when the samples were analyzed by immu­
noblotting (Figure 2). AQP2 antibodies demonstrated 
a 29-kd AQP2 band in all four AD urine samples. No 
signal was detectable in D urine samples, except in 
the urine sample of Volunteer 2, in which a weak 
29-kd signal was obtained. To analyze the influence of 
diuresis or antidiuresis on the excretion of other 
proteins from tubular cells, Western blots were also 
analyzed for AQP1 and THP. In the kidney, AQP1 is 
exclusively expressed in the proximal tubules and 
descending limbs of Henle’s loop (21), whereas THP is
TABLE 1. AQP2/V2R mutation, sex, age, and medication of NDI patients
Annotation AQP2/V2R mutation Sex Age (yr) Medication Reference
AQP2-A Homozygous for 463del in AQP2 M 18 No (9)
AQP2-GR Homozygous for G64R in AQP2 F 30 Thiazide/amilorlde (9)
AQP2-RC Homozygous for R187C In AQP2 M 30 No <9)
AQP2-AT Homozygous for A147T in AQP2 M 4 Thiazide/indomethacin To be published
v2r-tn T204N in V2R M 6 Thiazide/amlloride (13)
V2R-A/+ Heterozygous for 337del2/wt in vy? F 12 Thiazide (14)
V2R-A 528del7 in V2R M 13 Thiazide/amlloride (13)
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Figure 1. Coomassie blue-stained polyacrylamide gel of 
diuretic (D) and antidiuretic (AD) urine samples from four 
healthy volunteers (1-4). Elghteen-^g protein-equivalents 
were loaded. The molecular mass of marker proteins (in kd) 
is indicated.
1 2 3 4




Figure 2. Immunoblot analysis of AQP1, AQP2, and THP in 
diuretic (D) and antidiuretic (AD) urine samples from four 
healthy volunteers (1-4). Eighteen- jug protein-equivalents of 
urine samples were separated by SDS-PAGE and blotted. 
AQP1, AQP2, and THP proteins were visualized by chemilu- 
minescence autoradiography.
localized to the thick ascending limbs of Henle’s loop 
and early distal convoluted tubules (22). With AQP1 
antibodies, the 28-kd AQP1 band was detected in 
some D urine samples, but considerably more AQP1 
was observed in all AD urine samples (Figure 2). For 
THP, both the nonglycosylated band of 87 kd and the 
glycosylated 97-kd band were detected in D and AD 
urine, and again, larger amounts were present in AD 
urine (Figure 2). Immunoblot analysis of fractionated 
antidiuretic urine and subsequent densitome trie 
scanning revealed that 40% of urinary AQP1 and 
AQP2 is contained in the 200,000-g pellet, whereas 
the remaining 60% is found in the 200,000-g super­
natant (Figure 3). Urinary THP was totally sedimented 
in the 4000-tji pellet. With the AQP1, AQP2, and THP 












Figure 3. Immunoblot analysis of AQP1, AQP2, and THP in 
fractions of antidiuretic urine, Urine was concentrated 
(conc.) or consecutively centrifuged for 15 min at 4000 g 
(15'-4k), 30 min at 17,000 g (30#-17k), and 1 h at 200,000 g  
(1h-200k-p). Relative volume-equivalents of the concen­
trated urine, of the resuspended pellets of the different 
centrifugation steps, and of the remaining supernatant (lh- 
200k-s) were separated by.SDS-PAGE and blotted. AQP1, 
AQP2, and THP proteins were visualized by chemilumlnes- 
cence autoradiography.
NDI Patients
To determine whether AQP2 proteins are present in 
the urine of NDI patients carrying mutations In the 
AQP2 or V2R genes (Table 1), the urine samples of 
seven patients were concentrated and subjected to 
immunoblotting (Figure 4). D and AD urine samples of 
Volunteer 4 (Figures 1, 2) were included as controls 
(Lanes 4-D and 4-AD, respectively). A strong signal for 
the expected 29-kd AQP2 band was obtained in AD 
urine of the healthy volunteer and in the urine sample 
of the female NDI patient who was heterozygous for a 
V2R mutation (Lane V2R-A / + ). Furthermore, the male 
patient with a deletion in the V2R gene (Lane V2R-A) 
showed a weak AQP2 signal compared with the AD 
urine of the healthy volunteer. No AQP2 signal was 
detected in the urine of any of the four patients with
AQP2 V2R 4 4 V2R
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Figure 4. Immunoblot analysis of AQP1 and AQP2 in urine 
samples of NDI patients. The annotations and mutation In the 
AQP2 gene (AQP2) or VSR gene (V2R) are given in Table 1. 
For comparison, diuretic (D) and antidiuretic (AD) urine 
samples of healthy individual 4 were loaded. AQP1 and 
AQP2 were visualized by chemiluminescence autoradiogra­
phy. Fluid intake was ad libitum.
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mutations in the AQP2 gene nor in urine of the male 
patient whose V2R gene encodes a T204N substitu­
tion. Staining of an identical blot with AQP1 antibod­
ies revealed AQP1 signals at the expected 28 kd in 
urine samples of all NDI patients (Figure 4). In the 
urine of three patients with mutations in the AQP2 
gene (AQP2-A, AQP2-GR, and AQP2-RC), the AQP1 
signals were weak even when compared with D urine 
of the healthy volunteer. However, the intensity of the 
AQP1 signals in urine of one patient with a mutation 
in AQP2 (Lane AQP2-AT), and all patients with V2R 
mutations (V2R-TN, V2R-A/ + , and V2R-A) was similar 
to the intensity of the AQP 1 signal in AD urine of the 
healthy volunteer.
Because AQP1 is also present in erythrocytes, de­
tected AQP 1 proteins in urine might derive from eryth­
rocyte membranes. To test this possibility, the urine 
samples were analyzed for the presence of spectrin, a 
200- to 240-kd protein abundantly and specifically 
expressed in erythrocytes (20). Immunoblotting of 
different amounts of isolated erythrocyte ghost mem­
branes, together with urine proteins from five NDI 
patients and Volunteer 4, revealed that urine AQP1 
signals were similar to AQP1 levels between 0.18 and 
1.8 /xg of red blood cell membrane proteins (Figure 5). 
Identical bands and relative intensities were obtained 
with rabbit antibodies directed against the N-termi­
nus of AQP1 (not shown). Analysis of the same blot 
with erythrocyte spectrin-specific antibodies revealed 
a clear band of > 200 kd in a 0.018-/xg protein 
equivalent of erythrocyte ghost membranes (Figure 5). 
No spectrin signal was detected in lanes containing 
urine samples, even after longer exposure times.
DISCUSSION
<,
In urine, a wide variety of proteins is present, in­
cluding approximately 40% albumin, 15% immuno­
globulins, and 40% tissue proteins originating from 
renal and other urogenital tissues (23). However, the 
relative abundance of nephron constituents in urine is 
not constant because it shows intra- and interindi­
vidual variability and is also influenced by short-term 
physiological factors, such as urinaiy flow rate, age, 
sex, and circadian rhythm (24). The clear differences 
in Coomassie-stained protein profiles (Figure 1) and 
detected levels of AQP1, AQP2, or THP excretion (Fig­
AQP2 VgR 4 Ery membr.
A GR RC AT TN AD D .018 .18 1.8 18
S p e c t r . 
AQP1
Figure 5. Immunoblot analysis of AQP1 and spectrin proteins 
in urine samples of NDI patients and erythrocyte ghost 
membranes. The annotations of NDI patients and the 
healthy individual are given in Table 1. The amounts of 
proteins of erythrocyte ghost membranes (Ery membr.) are 
indicated (.018 to 18 ju,g).
ure 2) in D urine or AD urine samples of different 
healthy individuals underscore the interindividual 
variability. Furthermore, the intraindividual differ­
ences between D and AD urine samples corroborate 
the influence of urinary flow rate and circadian 
rhythm on urinary protein content. In this respect, the 
shift to more LMMP in D urine samples, compared 
with corresponding AD urine samples, is remarkable 
(Figure 1). Usually, LMMP, which pass through the 
glomerular filter, are almost completely reabsorbed 
and catabolized by the proximal tubule (25). However, 
in diuresis, the observed high excretion of LMMP has 
been ascribed to a decreased reabsorption in proximal 
tubules (23,24,26). The relatively high content of 
blood LMMP in diuretic urine explains the relatively 
low levels of AQP1, AQP2, and THP in these urine 
samples, compared with AD urine. Induction of AQP2 
expression in antidiuresis, however, also appears to 
contribute to elevated AQP2 levels in AD urine. In 
dehydrated rats, renal AQP2 mRNA and protein levels 
are increased upon activation of the V2R (2,27-30). In 
NDI patients with V2R mutations, a similar mecha­
nism appears to occur: in the urine of the patients 
without a functional V2R, AQP2 is not, or is hardly, 
detectable (Figure 4: Lanes V2R-TN and V2R-A), 
whereas in the urine of the patient encoding one 
mutant and one functional V2R, strongly elevated 
AQP2 levels are detected (Figure 4: Lane V2R~A/ + ). 
Low AQP2 levels in urine of NDI patients with V2R 
mutations and increased levels of urinary AQP2 in 
healthy humans after dehydration (or A VP injection) 
have also been found by others (31). Interestingly, 
fractionation of AD urine revealed that 40% of all 
urinary AQP1 and AQP2 is contained in the 200,000-g 
pellet, whereas the remaining 60% is found in the 
supernatant. A similar amount of AQP2 in the 
200,000-g pellet has been found by others (31). Appli­
cation of the used fractionation protocol to homoge­
nized kidneys of rats treated with l-desamino-8- 
D - arg in ine- vasop ress ion  re v e a le d  that AQP1 was en­
riched in a plasma membrane fraction (17,000 g)t 
whereas AQP2 was found in plasma membranes and 
in intracellular vesicles (200,000-g pellet) (12). Appar­
ently, urinary AQP1 and AQP2 sure present in small 
vesicles only. Whether urinary AQP 1 and AQP2 stem 
from intracellular vesicles released from renal cells or 
from shedded cells remains to be established. The 
solubilized form of AQP1 and AQP2 could well be a 
consequence of high urea concentrations in AD urine.
Mutant proteins that fold incorrectly or that are not 
assembled properly in vivo are mostly retarded in the 
endoplasmic reticulum and are typically degraded in a 
pre-Golgi compartment (32,33), Until now, missense 
AQP2 proteins in NDI patients have been shown to be 
nonfunctional and impaired in their targeting to the 
plasma membrane of Xenopus oocytes. The mutant 
Argl87Cys AQP2, however, was more stable, whereas 
Gly64Arg and Ser216Pro AQP2 were less stable than 
wild-type AQP2 (10). Because the osmolality of the 
urine of NDI patients {e . g see References 9,13) is in
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the same range as that of the D urine of control 
subjects, and because AQP2 could not be detected in 
D urine samples from healthy individuals (Figure 2), 
the lack of detection of AQP2 in the urine of NDI 
patients could be anticipated. However, NDI patients 
may not be comparable with control individuals in 
diuresis, because they have a physiological need to 
concentrate their urine. Therefore, to address the 
stability of AQP2 proteins in urine of NDI patients with 
mutations in the AQP2 gene, the best positive control 
would be the urine of an NDI patient with expression 
of a functional V2R to induce expression of a wild-type 
AQP2 protein. In the female NDI patient, whose V2R 
alleles encode a wild-type V2R and a truncated V2R, 
the disease has been explained by skewed inactiva­
tion , resulting in low expression of the wild-type V2R 
allele (14). Analysis of her urine (Figure 4: Lane V2R- 
A / + ) revealed an AQP2 signal comparable with that of 
the AD control. This indicates that in an NDI patient 
expressing only a limited amount of functional V2R, 
enough wild-type AQP2 is synthesized and excreted to 
be clearly detectable in urine. Because in our NDI 
patients carrying AQP2 gene mutations, a mutation in 
the V2R gene is unlikely or has been excluded (8,9), 
the absence of AQP2 in their urine must be attributed 
to reduced stability of the mutant AQP2 proteins. The 
urine from one patient (AQP2-A) served as a negative 
control, because his AQP2 gene encodes truncated 
AQP2 proteins, which will not be recognized by our 
antibody. Consequently, no conclusion can be drawn 
concerning the stability of these mutant AQP2 pro­
teins.
The differences in stability between missense AQP 2 
proteins and wild-type AQP2 in humans, as con­
cluded from the study presented here, seem more 
pronounced than previously concluded from expres­
sion studies in Xenopus oocytes (10). This difference is 
most likely the result of a smaller amount of AQP2 
mRNA present in collecting tubule cells compared 
with the amount injected into oocytes. Furthermore, 
as has been shown for the insulin receptor (34,35), 
mutant AQP2 proteins in collecting tubule cells might 
downregulate their own mRNA expression, a phenom­
enon that does not occur in oocytes. A similar situa­
tion has been described in a person whose AQP1 gene 
encoded a P38L mutation (11). In the urine of this 
person, AQP1 could not be detected, whereas after 2 
days of expression in Xenopus oocytes, this mutant 
AQP1 protein had a stability similar to wild-type
AQP1.
No spectrin could be detected in the urine samples, 
whereas in red blood cell membranes containing sim­
ilar amounts of AQP1 as the urine samples, the spec­
trin signal was strong (Figure 5). Therefore, urinary 
AQP1 must be of renal origin. Compared with the 
AQP1 signal in the AD control subject» the excreted 
amounts of AQP1 were similar in all NDI patients with 
a V2R mutation and in one patient with an AQP2 
mutation. In the urine of the other three NDI patients 
with AQP2 mutations, AQP1 signals were weak (Fig-
ure 4). Interestingly, except for two of these latter 
three patients (AQP2-A, AQP2-RC), all patients were 
on hydrochlorothiazide treatment combined with ei­
ther indomethacin or amiloride (Table 1). Further­
more, the patients with a strong AQP1 signal were 
younger than 14 yr, whereas the others were above 18 
yr. The detection of increased levels of AQP1 in urine 
of the majority of NDI patients using medication may 
indicate that the increased reabsorption of water in 
proximal tubules and descending limbs of Henle’s 
loop through treatment with thiazides in combination 
with amiloride or indomethacin is partly mediated by 
increased AQP1 expression levels.
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